Filing Flows › 10x Genomics (TXG) › Q1 2025
10x Genomics (TXG) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
10x Genomics (TXG) reported revenue of $155M for the first quarter 2025 (Q1 2025), +10% from a year earlier and -6% from the quarter before. Operating margin was -25.4%, net loss $34.4M (22.2% of revenue).
10x Genomics, Q1 2025: revenue $155M (+10% year over year), operating margin -25.4%, net loss $34.4M, operating cash flow $34.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $155M | -6% | +10% |
| Operating profit | −$39.3M | — | — |
| Net earnings | −$34.4M | — | — |
| Operating cash flow | $34.4M | — | — |
| Free cash flow | $32.5M | — | — |
What changed
Revenue was $154.9M in Q1 2025, up 10% year over year and down 6% from the previous quarter. Chromium was the largest line at 54% of revenue. License and royalty revenue added $17.1M year over year (up 1705900%), 123% of the total change. Spatial declined 49%.
Gross margin was 68.1%, up 2.2 points from a year earlier. Operating costs exceeded revenue by $39.3M, an operating margin of -25.4%. Operating expenses fell 6% while revenue rose 10%. The quarter ended with a net loss of $34.4M, narrower than the previous quarter's $49.0M loss.
Operating cash flow was $34.4M. Non-cash charges added back $8.0M of depreciation and amortization and $31.1M of share-based compensation. Working capital and other items added $29.6M. Capital expenditures of $1.9M left free cash flow of $32.5M.
Questions
What was 10x Genomics' revenue in the first quarter 2025?
10x Genomics (TXG) reported revenue of $155M for the first quarter 2025 (Q1 2025), +10% from a year earlier and -6% from the quarter before.
Was 10x Genomics profitable in the first quarter 2025?
Operating loss was $39.3M (-25.4% of revenue) and net loss $34.4M.
Source: 10x Genomics 10-Q on SEC EDGAR.